Translation, revision, and validation of the Chinese version of the Satisfaction with Oral Anti-Diabetic Agent Scale (C-SOADAS) in patients with type 2 diabetes mellitus

Yi-Ju Lin¹
Chin-Yuan Wang²
Elizabeth H Chang¹,³,⁴
Ssu-Wei Cheng⁵
Yu Ko¹,⁴

¹Department of Clinical Pharmacy, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; ²Department of Internal Medicine, Division of Endocrinology and Metabolism, National Taiwan University Hospital, Taipei, Taiwan; ³Department of Pharmacy, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; ⁴Research Center for PharmacoEconomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; ⁵Department of Pharmacy, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

Objective: The aim of this study was to translate, adapt, and validate the Satisfaction with Oral Anti-Diabetic Agent Scale (SOADAS) in type 2 diabetes mellitus (DM) patients taking oral antidiabetic drugs (OADs) in Taiwan.

Patients and methods: The SOADAS was translated to Chinese and was modified based on reviews of two physicians, five diabetes educators, and two patient focus groups. A cross-sectional interviewer-administered survey was conducted in adult patients with type 2 DM who were taking OADs. The Chinese version of the SOADAS (C-SOADAS), the EuroQol 5 dimensions 3-level (EQ-5D-3L) questionnaire, and a demographic questionnaire were administered to participants. Instrument structure, internal consistency, convergent validity, and known-group validity were assessed.

Results: A total of 260 DM patients were recruited. The mean score of an individual item ranged from 3.6 to 3.9, while the mean total score (out of 25 possible points) was 18.7 points. Overall, floor and ceiling effects were negligible. The Cronbach’s α value was 0.81. All the four predetermined hypotheses for known-group validity assessment were fulfilled. In convergent validity testing, the C-SOADAS total scores were found to be correlated with EuroQol-Visual Analog Scale (EQ-VAS) scores (r = 0.2; p < 0.01) but not with EuroQol 5 dimensions (EQ-5D) index scores (r = 0.02; p = 0.81).

Conclusion: The 5-item C-SOADAS appears to be a psychometrically acceptable measure of OAD treatment satisfaction among type 2 DM patients in Taiwan. The tool may be incorporated into clinical practice to quickly assess treatment outcomes from patients’ perspectives.

Keywords: diabetes mellitus, oral antidiabetic agent, satisfaction, validation, reliability, C-SOADAS, Taiwan

Introduction

Diabetes mellitus (DM) is a chronic disease that causes the body to deteriorate overtime. More than 400 million people live with DM worldwide.¹ The global DM prevalence has increased from 4.7% in 1980 to 8.5% in 2014, and it is estimated that the significant impact of DM will affect approximately 180 million people by 2025.²³ A similar increase has been observed in Taiwan with the DM prevalence rising from 4.8% in 2007, 6.4% in 2009, and 7.1% in 2012 to 10.0% in 2015.¹⁴

Given that patients’ perceptions of treatment outcomes may vary from clinicians’ judgments,⁵ it has become an important approach to evaluate treatment outcomes from patients’ perspectives using instruments to assess patients’ satisfaction or health-related quality of life (HRQoL). In addition, compared to generic measures, disease-specific
Instruments are generally more responsive to changes and can target the concerns of patients with that particular disease. Several patient-reported diabetes-specific instruments have been developed and validated to evaluate the overall impact of DM and its treatment on various aspects of an individual’s HRQoL. For example, the audit of diabetes-dependent quality of life is a 19-item HRQoL instrument designed to measure patients’ perceptions of DM impact, and this instrument has been translated into more than 20 languages. Another recommended DM-specific HRQoL measure is the diabetes care profile, which has demonstrated good reliability and validity in a number of studies.

In addition to HRQoL, another important patient-reported outcome is treatment satisfaction, particularly satisfaction with medications. According to the Centers for Disease Control and Prevention (CDC), patients taking pills only, without insulin, accounted for more than 50% of DM patients in the US in 2011. In Taiwan, it is reported that a majority (87.5%) of DM outpatients take oral antidiabetic drugs (OADs) only. In spite of the significant and still growing number of patients taking OADs for their DM treatment, few patient-reported DM instruments have targeted OADs either alone or along with the assessment of insulin satisfaction. An exception is the instrument developed and validated by Donatti et al; the Satisfaction with Oral Anti-Diabetic Agent Scale (SOADAS), which was the first treatment satisfaction instrument specific to OADs. The SOADAS was drafted by focus groups and cognitive debriefing interviews with type 2 DM (T2DM) patients taking OADs, and its psychometric properties were further evaluated in a cross-sectional sample of 106 DM patients and their physicians at their clinics.

In view of escalating DM prevalence and the large proportion of DM patients taking OADs in Taiwan as well as the growing number of OADs available and their increasing uses in clinical practice, we conducted this study with the aim of translating, adapting, and validating the SOADAS in T2DM patients taking OADs in Taiwan.

Patients and methods

This study is a cross-sectional interviewer-administered survey that was approved by the institutional review board of Shin-Kong Memorial Hospital (approval no SKH-20150712R).

Study setting and participants

The interviews were conducted in the endocrinology and metabolism clinics of an 862-bed medical center in Taipei from October 2016 to April 2017. Patients were recruited if they met the following criteria: 1) diagnosis of T2DM, 2) age 20 years or older, 3) taking one or more oral medications for diabetes, and 4) normal cognitive function (ie, no cognitive impairment such as Alzheimer’s disease, Parkinson’s disease, or dementia). Patients who used solely insulin for DM treatment were excluded.

Survey instrument

Translation and adaptation of the SOADAS

The SOADAS is the first treatment satisfaction measure developed specifically for OADs. The measure contains six items that focus on tolerability, medication’s ability to control blood sugar and diabetic symptoms, onset of action, effect on weight, and overall satisfaction. Each item is scored on a 5-point scale ranging from 1 (extremely dissatisfied) to 5 (extremely satisfied). The SOADAS has shown good internal consistency (Cronbach’s α = 0.86). In addition, the SOADAS has demonstrated convergent validity, as it was highly correlated with the Treatment Satisfaction Questionnaire for Medication (r = 0.71, p < 0.0001).

The translation of the SOADAS to Chinese was performed by a professional bilingual translator and revised by a group of health care professionals and two patient focus groups. The health care professionals included two physicians and five diabetes educators with an average of 19.1 practice-years in diabetes care. These experts were interviewed individually and were asked to examine the items for their importance and clarity as well as their relevance and applicability to local DM population. After the interviews, the SOADAS items were revised according to comments received and issues observed. The modifications included the removal of two items and the addition of a new item. Specifically, the health care professionals suggested the elimination of the question about “how quickly the medication controlled blood sugar?” Their reasoning was that patients on OADs do not monitor their blood sugar as regularly as those taking insulin and that DM patients in Taiwan tend to focus more on a drug’s effect rather than its onset of action. In addition, the experts suggested removing the question regarding the medication’s ability to control diabetic symptoms. The diabetes educators interviewed particularly pointed out that this question was misleading given that patients in Taiwan are educated to control their blood sugar instead of diabetic symptoms. Finally, based on the experts’ clinical experience, they advised the addition of a new item that assessed the convenience of taking the OAD, which they believed could influence patients’ satisfaction with the drug. The revised SOADAS was subsequently validated in Taiwan. The expert panel for the translation included two professional bilingual translators, five diabetes educators, and five physicians with an average practice-years in diabetes care of 19.1 years. The experts were selected based on their professional experience in diabetes care and their ability to represent the perspectives of patients and healthcare providers. The validation process included forward translation of the SOADAS from English to Chinese, back translation of the Chinese version to English, and review by the expert panel. The final Chinese version of the SOADAS was approved by the expert panel, and the reliability and validity of the Chinese version were assessed in a separate study. The results of the validation study demonstrated that the Chinese version of the SOADAS had good reliability and validity, with a Cronbach’s α of 0.86 and a test–retest reliability of 0.91. The Chinese version of the SOADAS was subsequently used in a study to evaluate treatment satisfaction in T2DM patients taking OADs in Taiwan. The results of the study showed that the Chinese version of the SOADAS had high psychometric properties, with a Cronbach’s α of 0.86 and a test–retest reliability of 0.91. The study also demonstrated that the SOADAS was responsive to changes in treatment satisfaction, with a correlation coefficient of 0.86 between the SOADAS and the Treatment Satisfaction Questionnaire for Medication (TSQM). The findings of the study provided evidence for the use of the Chinese version of the SOADAS in clinical practice and research in Taiwan. The study was approved by the institutional review board of the hospital where it was conducted, and all participants provided informed consent before participation. The study was funded by a grant from the National Science Council of Taiwan. The results of the study were published in a peer-reviewed journal, and the study data and materials are available upon request from the corresponding author.
tested in two patient focus groups that consisted of a total of seven T2DM patients. The patients confirmed that the revised questions were comprehensible and adequately reflected the characteristics of OADs that they cared about.

The final Chinese version of the SOADAS (C-SOADAS) contained five items that assessed patients’ satisfaction with their oral antidiabetic medication’s ability to control blood sugar, its effect on weight, the tolerability of its side effects, dosing regimen convenience, and overall satisfaction. Similar to the original SOADAS, each item had response choices presented on a 5-point scale ranging from 1 (extremely dissatisfied) to 5 (extremely satisfied). The scores of the five items were summed to generate a total score ranging from 5 to 25, with higher scores indicating greater satisfaction.

EuroQol 5 dimensions 3-level (EQ-5D-3L) questionnaire
The EQ-5D-3L questionnaire is a generic health status measure developed by the EuroQol group which consists of a descriptive system and EuroQol-Visual Analog Scale (EQ-VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of the dimensions consists of three levels of response: no problems, some problems, and extreme problems. Responses to the five questions can be used to generate an index score ranging from 0 (death) to 1 (perfect health), where a score of <0 represents a health state considered worse than death. The Japan value set (or tariffs) was applied to compute the EuroQol 5 dimensions (EQ-5D) index score, because Taiwanese weights were not available at the time of study. The EQ-VAS portion of the EQ-5D-3L records respondents’ self-rated health on a scale from 1 to 100, with higher scores indicating a better general health status.

Demographic and clinical characteristics
In addition to the C-SOADAS and EQ-5D-3L, demographic and clinical data were also collected from the participants and, if available, their medical records, which included age, gender, education, height, weight, monthly income, DM duration (in years), presence of DM-related complications, most recent HbA1c (%), adherence to OAD(s), and whether they had a DM-associated hospitalization or emergency room (ER) visit in the past year. Adherence to OAD therapy was assessed by the following question: “In the past month, have you taken your oral antidiabetic medicine exactly as your doctor told you in terms of timing, dosing, and frequency?” with the response options of “never”, “seldom”, “sometimes”, “often”, and “always”.

Survey administration
After enrolling in this study, the participants were informed verbally about the study context and signed written informed consent. Then, they were asked to complete the SOADAS, the EQ-5D-3L, and the questionnaire collecting information about their demographic and clinical characteristics. Upon completion, participants received compensation equivalent to approximately US$15.

Statistical analyses
Descriptive statistics were used to examine the respondents’ and C-SOADAS items’ characteristics. Percentages of respondents who scored the lowest (5 points) and highest (25 points) possible C-SOADAS total scores were calculated to examine floor and ceiling effects. Internal consistency was assessed by Cronbach’s α with an α-value of >0.7 to demonstrate acceptable reliability.

Face validity was confirmed by the health care professionals and patient focus groups at the development phase. Principal component analysis was used to test the unidimensionality of the C-SOADAS. Construct validity was examined by exploratory factor analysis to identify the structure of the C-SOADAS. Convergent validity of the C-SOADAS was evaluated against the EQ-5D index and VAS scores by Pearson correlation. Known-group validity was assessed by examining whether the C-SOADAS could discriminate subgroups with different characteristics. Specifically, we hypothesized that a higher mean C-SOADAS total score would be observed in patients who were in good control of HbA1c (ie, most recent HbA1c ≤ 7%), had no DM-associated hospitalization/ER visit in the past year, or had fewer DM-related complications. Independent t-test and one-way analysis of variance (ANOVA), where appropriate, were used for testing these hypotheses. In addition, Spearman correlation analysis was performed to test the hypothesis that patients’ SOADAS total scores were positively associated with their adherence to OADs.

All statistical analyses were performed using IBM SPSS Statistics for Windows, version 19 (IBM Corporation, Armonk, NY, USA).

Results
Characteristics of study participants
A total of 260 DM patients participated in the C-SOADAS validation study. A summary of the participants’ demographic and clinical characteristics is presented in Table 1. The mean (±SD) age of the participants was 58.0 (±11.4) years. The proportion of participants who were males (56.2%) was
slightly larger than that of females (43.8%). The mean (±SD) DM duration was 9.9 (±7.4) years. Most of the participants’ highest education level was senior high school (44.2%), followed by college (19.2%) and junior high school (14.2%). Approximately half of the participants were obese (41.5%), had no income (45.4%), and were taking more than one OAD (55.7%). The most common DM-related complication reported was cardiovascular disease (35.8%), followed by diabetic neuropathy (18.1%) and diabetic retinopathy (12.7%). Approximately two-thirds (65.8%) of the participants had uncontrolled HbA1c (>7%), and the overall mean (±SD) HbA1c was 8.0% (±1.6).

Item level and total scores of the C-SOADAS

Table 2 represents the item level and total scores of the C-SOADAS. The mean score of an individual item ranged from 3.6 to 3.9, while the mean total score was 18.7 points. Very few participants provided a response of “extremely dissatisfied” to any item, whereas 5.4%–13.1% of study participants responded “extremely satisfied” to individual items. Overall, floor and ceiling effects were negligible, with 0% and 2.3% of the patients scoring the lowest and highest possible total scores, respectively. All five items had an item-total correlation coefficient of 0.7 or higher.

Reliability and validity assessment

The Cronbach’s $\alpha$ value was 0.81 for the C-SOADAS scores, indicating good internal consistency. Principal component analysis showed that the C-SOADAS was unidimensional with the first factor accounting for 59.3% of the total variance and an eigenvalue of 3.0, which was significantly higher than that of the second component (eigenvalue = 0.7) and those of the subsequent components. In convergent validity testing, the C-SOADAS total scores were found to be

Table 2 Characteristics of the C-SOADAS (n = 260)

<table>
<thead>
<tr>
<th>Item number</th>
<th>Mean</th>
<th>SD</th>
<th>Observed score</th>
<th>Floor (%)</th>
<th>Ceiling (%)</th>
<th>Item total correlation ($r$)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1: ability to control blood sugar</td>
<td>3.6</td>
<td>0.9</td>
<td>1–5</td>
<td>1.2</td>
<td>13.1</td>
<td>0.8</td>
</tr>
<tr>
<td>Q2: effect on weight</td>
<td>3.7</td>
<td>0.7</td>
<td>2–5</td>
<td>0</td>
<td>5.4</td>
<td>0.7</td>
</tr>
<tr>
<td>Q3: tolerability of the side effects</td>
<td>3.7</td>
<td>0.8</td>
<td>1–5</td>
<td>1.5</td>
<td>9.6</td>
<td>0.8</td>
</tr>
<tr>
<td>Q4: convenience of drug taking</td>
<td>3.9</td>
<td>0.6</td>
<td>1–5</td>
<td>0.4</td>
<td>10.4</td>
<td>0.7</td>
</tr>
<tr>
<td>Q5: overall satisfaction</td>
<td>3.8</td>
<td>0.6</td>
<td>2–5</td>
<td>0</td>
<td>8.8</td>
<td>0.9</td>
</tr>
<tr>
<td>Total C-SOADAS score</td>
<td>18.7</td>
<td>2.8</td>
<td>10–25</td>
<td>0</td>
<td>2.3</td>
<td></td>
</tr>
</tbody>
</table>

Note: *All $p < 0.000$.

Abbreviations: C-SOADAS, Chinese version of the Satisfaction with Oral Anti-Diabetic Agent Scale; Q, question.
correlated with EQ-5D VAS scores ($r = 0.2; p < 0.01$) but not with EQ-5D index scores ($r = 0.02; p = 0.81$).

All the four hypotheses were fulfilled. A higher C-SOADAS total score was associated with good control of HbA1c ($p < 0.0001$), the absence of DM-associated hospitalization/ER visit in the past year ($p = 0.049$), and better adherence to OAD therapy ($r = 0.17; p = 0.006$). Moreover, the ANOVA result showed that there were significant differences among patients with different numbers of DM-related complications ($p = 0.002$), and the post hoc Scheffe’s test showed that the mean SOADAS total score of the patients with no complication was higher than the scores of those with three or more complications ($p = 0.006$).

**Discussion**

This study aimed to translate and revise the original SOADAS to develop a Chinese version where the psychometric properties were then validated in T2DM patients in Taiwan. The study results indicate that C-SOADAS is a reliable measure for the assessment of patient satisfaction with oral antidiabetic medications as indicated by its high internal consistency. In addition, the C-SOADAS demonstrated convergent validity, as shown by its correlation with EQ-5D VAS scores, and known-group validity, given its ability to discriminate among known groups based on adherence, complications, DM control, and ER/inpatient visits.

The C-SOADAS shows psychometric properties similar to those of the original SOADAS developed and validated in the US. Specifically, both measures had a Cronbach’s $\alpha$ of 0.8, and the factor analysis yielded one factor solution in both studies, with the first factor accounting for approximately 60% of the total variance. Moreover, ceiling and floor effects were not evident in the C-SOADAS or in the original version, which indicates good discriminative ability. Furthermore, similar to the findings of previous satisfaction studies, higher HbA1c levels were found to be associated with lower treatment satisfaction in the current study. Finally, in the convergent validity assessment, it was found that C-SOADAS total scores were correlated with the EQ-5D VAS scores, but not with EQ-5D index scores. An explanation could be that a large proportion (63.5%) of our study participants scored the highest possible EQ-5D index score of 1.0, resulting in little variance among the scores and making them less discriminating than the EQ-5D VAS scores.

A notable change to the original SOADAS in the C-SOADAS was the removal of the question about a medication’s ability to control diabetic symptoms. Common symptoms of DM include frequent urination, thirst, extreme fatigue, and blurry vision. Given the fact that more than two-fifths of T2DM patients in Taiwan were more than 65 years of age, they were likely to perceive these DM symptoms to be part of aging, rather than indicators of OADs’ effectiveness. Another difference in the C-SOADAS is the addition of the evaluation of dosing regimen convenience, which was actually included in the original draft version of the SOADAS but was excluded from the final version. We decided to add this question because of experts’ suggestion at the development phase. The analysis results showed that the convenience item was highly correlated with total score, and no respondent had difficulty understanding or answering this question. However, a concern was raised from our observations with regard to the item examining an OAD’s effect on weight. A number of participants had difficulty answering this question because they tended to attribute the change in weight to their diet rather than the drug’s effect. Further examination of the appropriateness and psychometric properties of this item is needed.

For a chronic condition such as DM, it is important to take into account a patient’s perception of treatment outcomes. Indeed, it has been found that improvements in patient treatment satisfaction can improve treatment efficacy and adherence. The validated C-SOADAS could be used as an outcome measure in the future clinical trials of OADs that involve Chinese DM patients. It could also be incorporated into routine clinical practice as a quick assessment of OAD treatment from a patient’s perspective and as a way of identifying patients’ concerns or problems with their treatment. To enhance C-SOADAS’ usefulness and applicability, future study is needed to determine its minimal clinically important difference.

There are several limitations to this study. First, the study results may not be able to generalize to all T2DM patients due to the fact that our study participants were a convenience sample recruited from the outpatient clinics at a single hospital in Taiwan. The study sample could be representative of relatively healthy DM patients. Second, the responsiveness of the C-SOADAS could not be assessed due to the cross-sectional design of the current study. Third, although efforts were made to encourage the participants to give honest answers, ensuring them that their replies would have no consequences, socially desirable responses may not have been fully avoided, particularly to the C-SOADAS questions.
Conclusion
The 5-item C-SOADAS appears to be a psychometrically acceptable measure of OAD treatment satisfaction among T2DM patients in Taiwan. The C-SOADAS could be incorporated into clinical practice as a quick and useful tool that provides health care professionals with a good understanding of OAD treatment outcomes from patients’ perspective. Future study is needed to determine C-SOADAS’ minimal clinically important differences and to assess its responsiveness to detect change over time.

Keypoints
1. The Chinese version of the Satisfaction with Oral Anti-Diabetic Agent Scale (C-SOADAS) is a psychometrically acceptable measure of oral antidiabetic drug (OAD) treatment satisfaction among type 2 diabetes mellitus (DM) patients in Taiwan.
2. The developed and validated C-SOADAS could be incorporated into clinical practice as a quick and useful tool that provides health care professionals with a good understanding of OAD treatment outcomes from patients’ perspective.

Acknowledgment
This study was sponsored by AstraZeneca Taiwan Ltd (A-104-062) and the Shin Kong Ho-Su Memorial Hospital (SKH-8302-105-NDR04).

Disclosure
The authors report no conflicts of interest in this work.

References